NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $2.64 +0.04 (+1.35%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AbCellera Biologics Stock (NASDAQ:ABCL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AbCellera Biologics alerts:Sign Up Key Stats Today's Range$2.54▼$2.6350-Day Range$1.93▼$3.4752-Week Range$1.89▼$4.34Volume319,745 shsAverage Volume4.13 million shsMarket Capitalization$785.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingModerate Buy Company OverviewAbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More… AbCellera Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreABCL MarketRank™: AbCellera Biologics scored higher than 47% of companies evaluated by MarketBeat, and ranked 671st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 3 research reports in the past 90 days.Read more about AbCellera Biologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.56% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 3.64%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.56% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 3.64%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment0.97 News SentimentAbCellera Biologics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search InterestOnly 16 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders28.00% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Stock News HeadlinesIs AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?April 23 at 11:03 AM | msn.comWhat is Leerink Partnrs' Forecast for ABCL Q1 Earnings?April 20, 2025 | americanbankingnews.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 25, 2025 | Brownstone Research (Ad)Leerink Partners Remains a Buy on AbCellera Biologics (ABCL)April 19, 2025 | markets.businessinsider.comAbCellera Biologics (NASDAQ:ABCL) Price Target Raised to $5.00April 19, 2025 | americanbankingnews.comAbCellera price target raised to $5 from $4 at KeyBancApril 17, 2025 | markets.businessinsider.comAbCellera: Attractively Priced But A Catalyst Is NeededApril 16, 2025 | seekingalpha.comKeyBanc Remains a Buy on AbCellera Biologics (ABCL)April 16, 2025 | theglobeandmail.comSee More Headlines ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $2.93 at the beginning of the year. Since then, ABCL stock has decreased by 11.3% and is now trading at $2.60. View the best growth stocks for 2025 here. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings results on Monday, November, 4th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The company earned $6.51 million during the quarter, compared to analysts' expectations of $8.95 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 15.73% and a negative net margin of 533.32%. Read the conference call transcript. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' top institutional investors include TrueMark Investments LLC (0.04%), Salem Investment Counselors Inc. (0.03%), GEM Asset Management LLC (0.01%) and AssuredPartners Investment Advisors LLC (0.01%). Insiders that own company stock include Holdings Ltd Thermopylae, Veronique Lecault and Andrew Booth. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbCellera Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AUO (AUOTY). Company Calendar Last Earnings11/04/2024Today4/25/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABCL CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+188.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,400,000.00 Net Margins-533.32% Pretax Margin-613.32% Return on Equity-15.73% Return on Assets-12.22% Debt Debt-to-Equity RatioN/A Current Ratio9.34 Quick Ratio9.34 Sales & Book Value Annual Sales$28.83 million Price / Sales26.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.65Miscellaneous Outstanding Shares297,988,000Free Float212,664,000Market Cap$774.77 million OptionableOptionable Beta0.50 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ABCL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.